AUTERI, GIUSEPPE
 Distribuzione geografica
Continente #
NA - Nord America 957
EU - Europa 802
AS - Asia 222
AF - Africa 70
SA - Sud America 3
OC - Oceania 2
Totale 2.056
Nazione #
US - Stati Uniti d'America 952
IT - Italia 179
SE - Svezia 159
GB - Regno Unito 122
DE - Germania 118
VN - Vietnam 94
IE - Irlanda 63
IN - India 54
CN - Cina 42
BE - Belgio 36
TG - Togo 35
FR - Francia 29
RU - Federazione Russa 26
CI - Costa d'Avorio 19
JO - Giordania 16
BG - Bulgaria 14
FI - Finlandia 14
AT - Austria 11
CH - Svizzera 11
NG - Nigeria 10
EE - Estonia 9
ZA - Sudafrica 6
CA - Canada 5
IR - Iran 4
UA - Ucraina 4
PL - Polonia 3
TR - Turchia 3
BR - Brasile 2
ES - Italia 2
HK - Hong Kong 2
TW - Taiwan 2
AU - Australia 1
BD - Bangladesh 1
CL - Cile 1
GE - Georgia 1
HR - Croazia 1
HU - Ungheria 1
JP - Giappone 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
SG - Singapore 1
Totale 2.056
Città #
Chandler 197
Southend 110
Dong Ket 93
Ashburn 84
Fairfield 69
Dublin 63
Princeton 52
Bologna 47
Brussels 36
Lomé 35
Houston 33
Wilmington 29
Woodbridge 29
Seattle 28
Redmond 26
Ann Arbor 22
Milan 22
Turin 21
Cambridge 20
Abidjan 19
Bremen 18
Amman 16
Nanjing 16
New York 16
Berlin 14
Helsinki 14
Sofia 14
Westminster 14
Boydton 13
Vienna 11
Monheim 9
Bern 8
Abeokuta 7
Des Moines 7
Beijing 6
Medford 6
Saint Petersburg 6
Fremont 5
Norwalk 5
Falls Church 4
Florence 4
Leawood 4
Migliarino 4
Mountain View 4
Olalla 4
Paris 4
Redwood City 4
Rome 4
San Diego 4
Shenyang 4
Toronto 4
Andover 3
Cernusco sul Naviglio 3
Changsha 3
Lagos 3
Limidi 3
Modena 3
Nanchang 3
Pune 3
San Francisco 3
Central 2
Chicago 2
Fiesole 2
Hefei 2
Hounslow 2
Kuban 2
Los Angeles 2
Madrid 2
Poggio Renatico 2
Romainville 2
Taipei 2
Taizhou 2
Torino 2
Zanjan 2
Zhengzhou 2
Abano Terme 1
Auckland 1
Bagnacavallo 1
Boardman 1
Bonn 1
Budapest 1
Canberra 1
Capo D'orlando 1
Casalecchio di Reno 1
Castel Maggiore 1
Catanzaro 1
Changchun 1
Charlotte 1
Clearwater 1
Cortona 1
Cutrofiano 1
Dearborn 1
Delhi 1
Duino 1
Edinburgh 1
Faisalabad 1
Forlì 1
Formigine 1
Frankfurt am Main 1
Haikou 1
Totale 1.370
Nome #
CIRCULATING CD34+ STEM/PROGENITOR CELLS FROM TRIPLE NEGATIVE PATIENTS WITH MYELOFIBROSIS SHOW DIFFERENT NUMBER, GENE EXPRESSION PROFILE AND IN VITRO RESPONSE TO INFLAMMATORY STIMULI AS COMPARED WITH THE JAK2(V617F) MUTATED COUNTERPARTS 135
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients 134
Mobilized Peripheral Blood versus Cord Blood: Insight into the distinct role of proinflammatory cytokines on survival, clonogenic ability, and migration of CD34+ cells 132
Circulating Platelet Vs Megakaryocyte-Derived Microparticles Identify Myelofibrosis Patients with JAK2V617F Mutation, High Disease Burden and Ruxolitinib Response 128
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 126
Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis 122
Disease-specific derangement of circulating endocannabinoids and n-acylethanolamines in myeloproliferative neoplasms 117
Distinct profile of CD34+ cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease 95
A specific host/microbial signature of plasma-derived extracellular vesicles is associated to thrombosis and marrow fibrosis in polycythemia vera 91
An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera 89
Understanding how older age drives decision-making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients 87
STUDIO DELLA FUNZIONE E DEL PROFILO DEI MICRORNA IN MICROPARTICELLE CIRCOLANTI ISOLATE DA PAZIENTI ‘TRIPLI NEGATIVI’ E JAK2V617F MUTATI CON MIELOFIBROSI 78
TOWARD THE IDENTIFICATION OF A MICRORNA-BASED SIGNATURE OF CIRCULATING MICROPARTICLES FROM TRIPLE NEGATIVE AND JAK2(V617F) MUTATED PATIENTS WITH MYELOFIBROSIS 76
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 73
null 68
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. 68
The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis 57
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data 56
The diagnostic role of next generation sequencing in uncovering isolated splenomegaly: A case report 54
Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years. 51
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis 45
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 44
Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS-13 activity and autoantibodies 43
Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia 36
Telemedicine in patients with haematological diseases during the coronavirus disease 2019 (COVID-19) pandemic: selection criteria and patients’ satisfaction 33
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎ 26
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome 26
IDENTIFICATION OF POLYCYTHEMIA VERA-SPECIFIC BIOMARKERS OF OUTCOME BY NOVEL MULTIDIMENSIONAL ANALYSIS APPROACHES 19
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis 18
Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity 16
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients 13
Spleen and Liver Fibrosis Is Associated to Treatment Response and Prognosis in Philadelphia-Negative Chronic Myeloproliferative Neoplasms 7
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis 1
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome 1
Sustained response off therapy after fostamatinib: A chronic refractory ITP case report 1
Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study 1
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib 1
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy 1
Immune Thrombocytopenia Onset and Relapse During the COVID-19 Pandemic. A Monocenter Study 1
Totale 2.170
Categoria #
all - tutte 6.462
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.462


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201925 0 0 0 0 0 0 0 0 1 9 3 12
2019/2020244 48 8 0 13 22 19 25 38 27 21 17 6
2020/2021295 37 14 8 2 2 17 7 23 50 3 8 124
2021/2022546 8 17 24 51 32 22 11 49 19 53 155 105
2022/2023790 56 100 45 104 62 78 19 49 147 30 61 39
2023/2024233 25 49 26 35 21 45 2 30 0 0 0 0
Totale 2.170